Genetic Counselling — Inherited Cancer Risk Guidance

Genetic counselling is a comprehensive clinical process provided by certified genetic counsellors or medical geneticists. It involves a systematic review of a patient's personal and multigenerational health background to determine the likelihood of a hereditary cancer syndrome. Counselors evaluate patterns of tumour types, ages of onset, and ancestral factors to estimate genetic predisposition.

Beyond risk assessment, genetic counselling provides education on the scientific principles of inheritance, benefits and limitations of molecular testing, and legal or insurance considerations. When testing is undertaken, counselling ensures results—whether positive, negative, or uncertain—are translated into clear, actionable clinical strategies for cancer prevention, surveillance, or targeted treatment.

Understanding hereditary cancer risk significantly influences medical management for both patients and their relatives. For an individual already diagnosed with cancer, identifying an underlying hereditary mutation can guide surgical choices, such as bilateral mastectomy instead of lumpectomy, or inform the selection of specific targeted therapies. For unaffected family members, finding an inherited alteration opens pathways for enhanced surveillance, lifestyle modifications, or risk-reducing medications and surgeries. Conversely, true negative results can relieve anxiety and prevent unnecessary medical interventions, ensuring that healthcare strategies remain proportionate and personalised.

Genetic counselling does not perform diagnostic testing directly; rather, it guides the selection of molecular laboratory tests. Counselors evaluate whether a patient should undergo single-gene analysis, targeted mutation panels, or comprehensive next-generation sequencing multi-gene panels. Testing is typically performed on genomic DNA extracted from a peripheral blood draw or saliva sample. Counselors help interpret findings such as pathogenic variants, benign variants, and variants of uncertain significance (VUS), advising whether further testing is warranted.

Genetic counselling frequently addresses hereditary breast and ovarian cancer syndromes associated with mutations in genes such as BRCA1 and BRCA2. It is also central in evaluating Lynch syndrome, which elevates risks for colorectal, endometrial, ovarian, and gastric cancers. Other conditions frequently requiring counselling include familial adenomatous polyposis, Li-Fraumeni syndrome, hereditary diffuse gastric cancer, von Hippel-Lindau disease, multiple endocrine neoplasia, and hereditary forms of prostate, pancreatic, and renal cell carcinomas across various age groups.

While genetic counselling itself is not a therapeutic intervention, its findings directly shape medical and surgical interventions. Confirming an inherited pathogenic variant may qualify patients for targeted pharmacological therapies, such as poly (ADP-ribose) polymerase (PARP) inhibitors in tumours with homologous recombination deficiency. It can also inform systemic immunotherapy choices in tumours demonstrating mismatch repair deficiency. Furthermore, counselling guides recommendations for preventive risk-reducing surgeries, such as prophylactic salpingo-oophorectomy, or tailored radiotherapy decisions.